Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: J Neurovirol. 2019 Jan 3;25(5):686–701. doi: 10.1007/s13365-018-0705-6

TABLE 1.

Comparison of Proposed Biomarkers

Biomarker Advantage & Utility Disadvantage & Constraints GOAL: Diagnostic Biomarker GOAL: Prognostic Biomarker
NFL Chain Concentration Plasma and CSF concentrations highly correlated; Sensitive to the initiation of cART Alterations have been observed in other neurodegenerative diseases (e.g., AD, multiple sclerosis), and thus, it is not disease specific Inconsistent relationship with NCI that may be driven primarily by cART In the pre-cART era, increases in NFL concentration were associated with presentation of ADC
Amyloid and Tau Proteins Distinct pathology from AD Invasive procedure needed for CSF measurements Selective relationships between NCI and protein markers; Unable to distinguish between milder forms of NCI and controls, despite the use of multiple markers CSF Aβ−42 and p-tau have been utilized as a prognostic biomarker for the conversion from MCI to AD
Resting-State fMRI Brief, non-invasive procedure Currently unclear what changes in BOLD signaling indicate mechanistically; Inconsistencies between studies Inconsistent relationship between fMRI measures and NCI No changes in resting-state fMRI relative to controls were observed in a two-year follow-up
Prepulse Inhibition Brief, non-invasive procedure; Clinically translational experimental paradigm Alterations have been observed in other diseases, albeit evidence in other neurodegenerative disease (e.g., AD) is limited Diagnostic utility generalizes across two experimental paradigms (i.e., cross-modal PPI, gap-PPI), the functional lifespan, sensory modalities, and biological sex; Overall high accuracy, sensitivity, and specificity Early neurocognitive impairments in PPI predict later alterations in higher order cognitive functions (r≥0.81)

NFL=Neurofilament Light; CSF=Cerebrospinal Fluid; cART=Combination Antiretroviral Therapy; AD=Alzheimer’s disease; NCI=Neurocognitive Impairments; ADC=AIDS Dementia Complex; Aβ−42=Amyloid β 1–42; MCI=Milder Cognitive Impairment; fMRI=Functional Magnetic Resonance Imaging; BOLD=Blood Oxygenation Level Dependent; PPI=Prepulse Inhibition; gap-PPI=Gap Prepulse Inhibition